Pharmaceutical Executive-11-01-2007

FDAAA aims to restore public trust in drug safety regulation but may curb investment in R&D

Approvable letters delay NDAs, cost pharma plenty, and are at an all-time high. Industry says FDA is gun-shy; the agency says it's business as usual. Who's right?

Top pharma brand experts discuss today's issues: safety, compliance, corporate branding, combatting generics, and more.

With ads on topics ranging from addiction to disease states, this year's Rx Club Award winners connect creativity with emotion

Business intelligence in a time of greater transparency is a whole new ball game. To play it well, be sure to look for surprising insights, expand your list of competitors of interest, and don't let Google be your only guide.

Will CROs continue to operate in India, or will Novartis' pullout send them farther East?

The impact of high-quality online training tools would be difficult and costly to replicate offline given the dynamic and interactive aspects offered

We have nothing to fear but the fear of change (with apologies to the wise Franklin D. Roosevelt). But we must get over that if we hope to make a real difference.